Trials / Terminated
TerminatedNCT02110992
Safety Study of SBRT and Docetaxel for Locally Recurrent or Second Primary Squamous Cell Carcinoma of the Head and Neck
A Phase I Pilot Study of SBRT and Concurrent Docetaxel for Reirradiation of Locally Recurrent or Second Primary Squamous Cell Carcinoma of the Head and Neck
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 7 (actual)
- Sponsor
- University of Cincinnati · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this research study is to test the safety of a chemotherapy drug called docetaxel and focused radiation therapy (SBRT) and see what effects (good and bad) it has on recurrent head and neck cancer that is not surgically removable.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Docetaxel | Docetaxel 15mg/m2 IV, given days 1, 8, and 15 during SBRT |
| RADIATION | Stereotactic Radiation | SBRT will be given over 5 fractions separated by \> 48 hours. Dose will be determined based upon dose escalation schedule and will range from 25-40 Gy. |
Timeline
- Start date
- 2014-04-01
- Primary completion
- 2017-03-29
- Completion
- 2017-03-29
- First posted
- 2014-04-10
- Last updated
- 2019-11-25
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02110992. Inclusion in this directory is not an endorsement.